ClinicalThought
Optimizing Immunotherapy for Advanced Non-Small-Cell Lung Cancer in Today’s Patients
Release Date: May 31, 2022
Expiration Date: May 30, 2023
Not certified for credit.
Begin »
Program Overview
Program Description
Experts discuss key points for optimizing the use of immune checkpoint inhibitor therapies, including individualizing therapy decisions and managing adverse events, in patients with advanced NSCLC.
Format
Clinical Thought
Target Audience
NPs and PAs in oncology
Faculty
Julia Rotow, MD
- Medical Oncologist
- Lowe Center for Thoracic Oncology
- Dana-Farber Cancer Institute
- Boston, Massachusetts
Details
This activity is supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Merck Sharp & Dohme Corp.; and Regeneron Pharmaceuticals, Inc and Sanofi.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Julia Rotow, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Chia Tai Tianqing, Eli Lilly, Gritstone Bio, Janssen, Jazz, Merck, Pfizer, Sanofi-Genzyme
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 104922O-CT6